Company intelligence / Profile preview

Meribel Pharma Solutions

United Kingdom

Ownership: Private
Employees: ~2000
Development stage: Other

Overview

Meribel Pharma Solutions is a mid-sized European CDMO, launched in 2025 and backed by Blue Wolf Capital Partners, providing development and commercial manufacturing services for oral solid, semi-solid, liquid, sterile multidose, lyophilised and sachet/stick-pack pharmaceutical products for human and veterinary health across 13 sites in France, Spain and Sweden.

Modalities: Small moleculeBiologic
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Meribel Pharma Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meribel Pharma Solutions.

Explore the full profile